Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo tackles rare lymphoma in early trial

NCT ID NCT04433156

Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of drugs called VR-CAP (bortezomib, rituximab, and chemotherapy) as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received up to 6 cycles of treatment. Researchers measured how long patients lived without the cancer getting worse and how many responded to treatment. The study is complete, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VR-CAP (bortezomib, rituximab, cyclophosphamide, epirubicin, prednisone)
What this could lead to
If successful, this could offer a new first-line treatment option for marginal zone lymphoma, potentially improving disease control and survival.
What could go wrong
This is a small, early-phase trial with only 26 participants and no comparison group. Results may not apply to all patients, and side effects from chemotherapy and targeted drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

26 people

The number who actually took part.

Started

Apr 2020

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 to 70 years old (including 18 and 70) 2. Diagnosed as marginal zone lymphoma 3. No receiving chemotherapy before enrollment 4. Indications for treatment: 1) symptoms related to tumor; 2) end-organ function damage; 3) large mass; 4) continuous or rapid progress of disease; 5) patient's willingness 5. Having at least one measurable lesions 6. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 0-1 7. Life expectancy no less than 3 months 8. enough main organ function 9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study 10. Agreeing to sign the written informed consents Exclusion Criteria: 1. Diagnosed as central nervous system lymphoma 2. World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) ≥2 3. Other malignant tumor history or active malignant tumor need be treated 4. Serious surgery and trauma less than two weeks 5. Systemic therapy for serious acute/chronic infection 6. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months 7. Active tuberculosis. Patients suspected of active TB need to be examined for chest X-ray, sputum and clinical symptoms and signs 8. HIV-positive, AIDS patients and untreated active hepatitis（HBV/HBV and HCV） 9. Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months 10. Patients with a history of mental illness 11. Researchers determine unsuited to participate in this trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Marginal zone lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Marginal zone lymphoma

Contacts and locations

Locations

  • Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

    Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.